Non-24-Hour Sleep-Wake Rhythm Disorder: Assessment, Treatments, Supplement Evidence and Safety

A sleep period that progressively drifts around the clock needs a different assessment from a fixed late bedtime. Non-24 is particularly associated with loss of useful light cues, but the actual pattern must be documented. Confidence is high in that distinction; treatment guidance and label facts are attributed with their population and funding limits. NHLBI pattern.

Table of contents

• Evidence summary
• What the condition is
• How it works
• The evidence-based treatments
• Supplement and lifestyle evidence
• What works and what is not established
• Risks and when to seek help
• Important interactions
• Who needs special assessment
• Clinician-led treatment and use
• Animal and in-vitro evidence
• Funding and source roles
• Frequently asked questions
• Sources and funding notes

Evidence summary

What the condition is

Non-24-hour sleep-wake rhythm disorder (Non-24) involves a sleep pattern that drifts relative to the 24-hour day rather than staying at a fixed late or early time. Sleep and wake periods may align with daily obligations for a while, then move out of alignment, producing recurrent insomnia or daytime sleepiness. NHLBI pattern.

It is especially relevant when blindness prevents normal light cues from reaching the circadian timing system. Sighted people can also need assessment for a drifting pattern, but evidence and treatment decisions should not simply be borrowed from blind-adult studies. A short diary taken during a relatively aligned period can be misleading. Light and blindness; Population limits.

Assessment starts with a diary of sleep onset, awakenings, final waking and naps across both obligation days and free days. Record light exposure, work or school timing, caffeine, alcohol and medicines. The important question is whether the pattern is stable, drifts over days, or lacks a sustained main sleep period. NHLBI assessment.

A clinician also checks whether another condition explains the symptoms. Actigraphy can help document timing; a sleep study or circadian hormone measurement may be useful in selected cases. A consumer watch can contribute a history but does not independently establish a circadian diagnosis. Testing should answer a specific clinical question rather than replace the account of daily function. Testing context.

How it works

The brain’s circadian clock responds to light and other daily cues. Sleep pressure builds with time awake; this is a related but different process. Being exhausted does not necessarily make the body clock ready for sleep. Age, inherited tendencies, neurological illness and daily light patterns can affect timing. Sleep/wake physiology; Causes and risk factors.

An internal cycle that is not adequately synchronized to daily cues can gradually slip across clock time. Loss of usable light information can matter, but visual diagnosis alone does not establish the actual sleep pattern. Non-24 is different from frequent intentional bedtime changes and from multiple irregular short sleep episodes. Circadian physiology; Pattern comparison.

The evidence-based treatments

The 2015 AASM guideline weakly recommends strategically timed melatonin for blind adults with Non-24, based on low-certainty evidence. It made no recommendation for sighted patients because data were insufficient. That is an evidence gap, not proof that sighted patients never benefit from individualized care. Original recommendation.

NHLBI also describes melatonin receptor agonists as clinical options for Non-24. A current US DailyMed record identifies tasimelteon capsules as indicated for adult Non-24. This is an attributed label fact, not an independent comparative efficacy conclusion, and local approvals may differ. Public treatment context; Manufacturer-supplied label.

Management needs a consistent, supervised plan and follow-up across the drifting cycle. The aim is sustainable synchronization and usable daily function, not merely falling asleep once after taking a product. If a medicine is proposed, discuss the target, interactions and how progress will be assessed. Follow-up.

Supplement and lifestyle evidence

Over-the-counter melatonin should not be assumed equivalent to a prescription receptor agonist or to the product used in a particular trial. Timing, formulation and actual content matter, and long-term safety questions remain. Blindness does not make a supplement interaction harmless. NCCIH cautions.

Light strategies depend on whether useful light signaling is available and on the measured pattern. General advice to get morning sunlight is not a sufficient treatment instruction for every person with Non-24. Discuss the sensory and practical context with the sleep service. Light-cue context; Individualized treatment.

What works and what is not established

A temporary period of good sleep does not necessarily establish sustained synchronization. Ask whether follow-up spans enough of the usual pattern to distinguish improvement from a naturally better-aligned interval. Symptoms, sleep timing and daily function should be considered together. Cyclic pattern; Monitoring.

The DailyMed efficacy section is manufacturer-supplied and is not used to rank tasimelteon against melatonin or declare a financially independent response rate. Likewise, the blind-adult guideline does not establish a sighted-patient effect. This article does not promise a cure or lifelong normalization. Source boundary; Evidence limits.

Risks and when to seek help

Seek assessment for a recurrent drifting sleep pattern, unpredictable sleepiness or inability to meet daily obligations. Avoid using a single apparently normal week to dismiss repeated impairment. Another sleep disorder, medicines or neurological condition may need separate evaluation. Assessment.

Do not drive or operate dangerous machinery when sleepy. Arrange transport and discuss work or school adjustments if alertness is unreliable. If sleep becomes worse, treatment causes adverse effects or the pattern changes, seek review instead of adding more products. Living safely.

Important interactions

Bright-light treatment is a timed intervention, not a request to look into the sun. Discuss eye disease and medicines that increase sensitivity to light with the clinician. Headache, eye strain, nausea or agitation can require adjustment. Light-therapy safety.

Melatonin can cause sleepiness and interact with medicines. NCCIH advises professional review for people taking blood thinners or with epilepsy and describes gaps for pregnancy, breastfeeding, children and long-term use. The amount in a supplement may differ from its label. A pediatric or adult prescription plan should not be replaced by an online brand claim. Safety and product limits.

Who needs special assessment

People with blindness, neurological conditions or a complicated medicine list may need coordinated care. A visually impaired person can have other sleep disorders as well; the diagnosis should be based on actual sleep history and appropriate testing. Sighted patients need an explicit discussion of the limited direct evidence rather than an automatic blind-adult regimen. Context; Evidence population.

The opened tasimelteon label warns of sleepiness and important metabolic drug interactions, including fluvoxamine and rifampin; severe liver impairment also needs consideration. Its adult indication does not establish pediatric safety. These facts should prompt medication review, not a do-it-yourself substitution. Label safety.

Clinician-led treatment and use

Bring a diary long enough to show the drift, not just your best week. Explain how the cycle affects meals, work, appointments and transport. Ask what evidence applies to your visual and neurological circumstances and how the plan will measure sustained benefit. Diagnostic framework.

Agree on a practical outcome: a more workable main sleep period, adequate sleep opportunity and better daily function, without new sedation or mood problems. Keep the diary during follow-up. Improvement in a clock measurement alone is not a complete patient outcome. This article gives no individualized melatonin dose, light intensity, exposure time or schedule-change prescription. Treatment framework; Follow-up.

Animal and in-vitro evidence

A cell experiment, animal clock shift or change in melatonin signaling cannot establish better sleep, school/work function or long-term safety in a person with this disorder. No animal or laboratory finding is used as a human efficacy verdict here.

Funding and source roles

A circadian disorder is not privately owned. Light-device makers, medicine/supplement suppliers and clinics can benefit from particular approaches. The original 2015 guideline reports AASM funding, no industry support and no financial author COI, alongside two society employees. That does not clear every underlying trial or the society’s entire revenue. Industry programmes and NHLBI finance are separately traced. Sources are predominantly US-based; no product batch or manufacturing origin was audited.

Tier describes financial proximity; A–D describes credibility for the stated source role. Neither is a clinical certainty grade. Unknown finances remain unknown. Manufacturer- and sponsor-funded efficacy is excluded from the independent verdict; attributed clinical guidance is identified as guidance.

Frequently asked questions

Is Non-24 just a very late bedtime?
No. A drifting pattern differs from a fixed delayed phase.

Does blindness automatically mean Non-24?
No. The actual sleep pattern needs assessment.

Can sighted people need assessment?
Yes, but the reviewed blind-adult recommendation cannot establish the same benefit in sighted people.

Is prescription tasimelteon the same as a melatonin supplement?
No. They are distinct products with different labeling and clinical decisions.

Why keep a longer diary?
To reveal drift and alternating periods of alignment and mismatch.

Sources and funding notes

NHLBI originals and the complete original 2015 AASM guideline, including funding and author disclosure, were opened. Guidance is identified by date and population. All original trials were not individually financially cleared; their effect sizes are not reproduced as an independent verdict. Animal studies, marketing and anecdotes are excluded from efficacy conclusions.

• NHLBI: circadian disorders overview — Condition family and biological-clock mismatch.
• NHLBI: circadian disorder types — Specific patterns; chronotype alone is not an illness.
• NHLBI: diagnosis — History, sleep diary and selected testing.
• NHLBI: causes and risk factors — Age, light cues, neurological disorders and contextual risks.
• NHLBI: symptoms — Sleepiness, insomnia and functional impairment.
• NHLBI: treatment — General care options; not financial clearance of treatment trials.
• NHLBI: living with circadian disorders — Follow-up and drowsy-driving safety.
• NHLBI: sleep/wake cycle — Clock, sleep pressure and environmental cues.
• AASM: original intrinsic circadian guideline, 2015 — Subtype/age-specific recommendations; no independently pooled efficacy estimate.
• NCCIH: melatonin — General safety and evidence limitations; not proof of a cure.
• AASM: industry programs — Society financial context only.
• NHLBI: budget and gift authority — Funding provenance only.
• Apotex tasimelteon: DailyMed label record — Adult US indication, somnolence/interactions only; efficacy excluded.

Last reviewed: October 4, 2026. Educational information; no personal diagnosis, medication dose or supplement regimen is supplied. Local approval, product labels and clinical circumstances may differ.